BR112018013271A2 - composições e métodos para detectar e tratar câncer de ovário - Google Patents
composições e métodos para detectar e tratar câncer de ovárioInfo
- Publication number
- BR112018013271A2 BR112018013271A2 BR112018013271A BR112018013271A BR112018013271A2 BR 112018013271 A2 BR112018013271 A2 BR 112018013271A2 BR 112018013271 A BR112018013271 A BR 112018013271A BR 112018013271 A BR112018013271 A BR 112018013271A BR 112018013271 A2 BR112018013271 A2 BR 112018013271A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- ovarian cancer
- detecting
- treating ovarian
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G01N33/57545—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307192 | 2015-12-31 | ||
| EP16305138 | 2016-02-05 | ||
| PCT/EP2017/050033 WO2017114972A1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018013271A2 true BR112018013271A2 (pt) | 2018-12-11 |
Family
ID=57821943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018013271A BR112018013271A2 (pt) | 2015-12-31 | 2017-01-02 | composições e métodos para detectar e tratar câncer de ovário |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11760808B2 (enExample) |
| EP (2) | EP3397964B1 (enExample) |
| JP (2) | JP6962920B2 (enExample) |
| KR (2) | KR102507685B1 (enExample) |
| CN (1) | CN108780091A (enExample) |
| AU (2) | AU2017204682B2 (enExample) |
| BR (1) | BR112018013271A2 (enExample) |
| CA (2) | CA3194356C (enExample) |
| EA (1) | EA037015B1 (enExample) |
| ES (2) | ES2901602T3 (enExample) |
| PL (1) | PL3397964T3 (enExample) |
| SG (1) | SG11201805605TA (enExample) |
| WO (1) | WO2017114972A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240018264A1 (en) * | 2015-12-31 | 2024-01-18 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating ovarian cancer |
| EP3720879B1 (en) * | 2017-12-05 | 2022-05-11 | Progastrine et Cancers S.à r.l. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
| AU2018381046B2 (en) | 2017-12-08 | 2025-10-02 | Ecs-Biotracker Sàrl | Radiolabeled progastrin in cancer diagnosis |
| TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ｅｃｓ前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
| WO2019166499A1 (en) | 2018-02-27 | 2019-09-06 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
| JP7687224B2 (ja) * | 2022-01-25 | 2025-06-03 | 株式会社三洋物産 | 遊技機 |
| JP7687223B2 (ja) * | 2022-01-25 | 2025-06-03 | 株式会社三洋物産 | 遊技機 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2008513536A (ja) * | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
| US7854932B2 (en) * | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| WO2008157383A1 (en) | 2007-06-15 | 2008-12-24 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis of ovarian cancer and lung cancer |
| EP2488551B1 (en) * | 2009-10-16 | 2018-07-25 | Progastrine et Cancers S.à r.l. | Monoclonal antibodies to progastrin and their uses |
| US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
| US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| US8900588B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| SG184092A1 (en) * | 2010-03-24 | 2012-10-30 | Biorealites | Prophylaxis of colorectal and gastrointestinal cancer |
| ES2871092T3 (es) | 2010-07-26 | 2021-10-28 | Progastrine Et Cancers S A R L | Métodos y composiciones para la terapia del cáncer de hígado |
-
2017
- 2017-01-02 US US16/067,151 patent/US11760808B2/en active Active
- 2017-01-02 CA CA3194356A patent/CA3194356C/en active Active
- 2017-01-02 PL PL17700480T patent/PL3397964T3/pl unknown
- 2017-01-02 CN CN201780013872.3A patent/CN108780091A/zh active Pending
- 2017-01-02 WO PCT/EP2017/050033 patent/WO2017114972A1/en not_active Ceased
- 2017-01-02 EA EA201891529A patent/EA037015B1/ru unknown
- 2017-01-02 AU AU2017204682A patent/AU2017204682B2/en active Active
- 2017-01-02 BR BR112018013271A patent/BR112018013271A2/pt not_active IP Right Cessation
- 2017-01-02 KR KR1020227022682A patent/KR102507685B1/ko active Active
- 2017-01-02 SG SG11201805605TA patent/SG11201805605TA/en unknown
- 2017-01-02 ES ES17700480T patent/ES2901602T3/es active Active
- 2017-01-02 KR KR1020187020588A patent/KR102428254B1/ko active Active
- 2017-01-02 ES ES21199551T patent/ES3015244T3/es active Active
- 2017-01-02 CA CA3009751A patent/CA3009751A1/en active Pending
- 2017-01-02 JP JP2018534923A patent/JP6962920B2/ja active Active
- 2017-01-02 EP EP17700480.1A patent/EP3397964B1/en active Active
- 2017-01-02 EP EP21199551.9A patent/EP3954999B9/en active Active
-
2021
- 2021-10-11 AU AU2021250840A patent/AU2021250840B2/en active Active
- 2021-10-13 JP JP2021167961A patent/JP7279761B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201891529A1 (ru) | 2019-01-31 |
| WO2017114972A1 (en) | 2017-07-06 |
| EP3397964A1 (en) | 2018-11-07 |
| KR20180105647A (ko) | 2018-09-28 |
| JP2022009080A (ja) | 2022-01-14 |
| CA3194356A1 (en) | 2017-07-06 |
| AU2021250840A1 (en) | 2021-11-04 |
| KR102507685B1 (ko) | 2023-03-08 |
| EP3954999A1 (en) | 2022-02-16 |
| EP3397964B1 (en) | 2021-09-29 |
| AU2017204682B2 (en) | 2021-07-29 |
| SG11201805605TA (en) | 2018-07-30 |
| EP3954999B9 (en) | 2025-03-12 |
| JP6962920B2 (ja) | 2021-11-05 |
| EP3954999C0 (en) | 2025-01-15 |
| AU2021250840B2 (en) | 2024-06-27 |
| KR102428254B1 (ko) | 2022-08-03 |
| ES2901602T3 (es) | 2022-03-23 |
| AU2017204682A1 (en) | 2018-07-19 |
| CA3009751A1 (en) | 2017-07-06 |
| EA037015B1 (ru) | 2021-01-27 |
| KR20220100100A (ko) | 2022-07-14 |
| CA3194356C (en) | 2025-04-08 |
| US11760808B2 (en) | 2023-09-19 |
| EP3954999B1 (en) | 2025-01-15 |
| JP2019502923A (ja) | 2019-01-31 |
| ES3015244T3 (en) | 2025-04-30 |
| CN108780091A (zh) | 2018-11-09 |
| PL3397964T3 (pl) | 2022-02-07 |
| JP7279761B2 (ja) | 2023-05-23 |
| US20190002582A1 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018013271A2 (pt) | composições e métodos para detectar e tratar câncer de ovário | |
| BR112018070919A2 (pt) | anticorpos anti-tim-3 e composições | |
| CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| BR112017000671A2 (pt) | moléculas com especificidade para cd79 e cd22 | |
| BR112018006360A2 (pt) | anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso | |
| BR112017023872A2 (pt) | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos | |
| BR112017027990A2 (pt) | modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38 | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| BR112016030908A2 (pt) | moléculas com especificidade para cd45 e cd79 | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| BR112017006368A2 (pt) | derivados de ácido borônico | |
| BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
| BR112017008799A2 (pt) | composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal | |
| BR112018000187A2 (pt) | composto, composição, método, e, uso de um composto ou composição | |
| BR112018002319A2 (pt) | anticorpos anti-cd154 e métodos de uso dos mesmos | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| BR112018013268A2 (pt) | composições e métodos para detectar e tratar câncer gástrico | |
| BR112019020414A2 (pt) | composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina | |
| BR112017009265A2 (pt) | apilimode para uso no tratamento do câncer colorretal | |
| BR112016018099B8 (pt) | Compostos funcionalizados de benzopiranos e uso dos mesmos | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| BR112019020412A2 (pt) | composições e métodos para detectar câncer de pulmão | |
| BR112017000303A2 (pt) | métodos para o tratamento de hipotensão | |
| BR112017024163A2 (pt) | compostos bicíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2651 DE 26-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |